SciSparc announces Phase IIa trial of ‘SCI-110’ to treat Alzheimer’s

upland-software-buys-bluevenn-for-52mn-to-boost-customer-engagement

Israel-based SciSparc Ltd.- a clinical-stage pharmaceutical firm that develops cannabinoid-based treatment solutions, has reportedly announced that it has entered into an agreement with the Israeli Medical Center for Alzheimer’s to facilitate a Phase IIa clinical study to analyze the tolerability, safety and efficacy of SCI-110 in the treatment of Alzheimer’s. For the record, the main objective of the trial is to ensure the efficacy and safety of the drug as well as to ensure the ability of the compound to ameliorate agitation among various other behavioral disturbances in patients suffering from Alzheimer’s disease. Notably, the study will be carried out after the receipt of all the necessary approvals from the Ministry of Health, Israel, and the Institutional Review Boards. The novel drug product, SCI-110 is a unique proprietary combination of Palmitoylethanolamide and Dronabinol. Seemingly, Alzheimer’s disease has emerged as one of the most common forms of dementia among people, accounting for nearly two-thirds of the total cases of dementia. This neurodegenerative disease leads to progressive and disabling impairment of cognitive functions like comprehension, memory, reasoning, attention, language, and judgment. Speaking along similar lines, some of the symptoms of the disease also depends on its stage. Neuropsychiatric symptoms such as social withdrawal, agitation, apathy, poor appetite, insomnia, wandering, and psychosis are some of the most common ones in the mid to late stages. Citing reports, the present pharmacological diagnosis of agitation in Alzheimers disease has showcased unsatisfactory results and often involves the use of off-label drugs. Antipsychotic drugs that are widely used drug forms for this purpose are considered better than placebo. Earlier known as Therapix Biosciences Ltd., SciSparc Ltd. is a specialty pharmaceutical firm which is led by a team of leading scientists and senior executives. At present, the company is developing drugs based on non-psychoactive cannabidiol-SCI 110 to treat Tourette syndrome and to treat sleep apnea. The company is also involved in the development of SCI-160 to treat pain and SCI-210 in the treatment of epilepsy and autism spectrum disorder. Source Credit: https://www.prnewswire.com/il/news-releases/scisparc-to-conduct-a-phase-iia-clinical-trial-in-alzheimers-patients-using-the-companys-proprietary-cannabinoid-based-treatment-301229931.html